Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non–Small-Cell Lung Cancer
Titel:
Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non–Small-Cell Lung Cancer
Auteur:
von Pawel, Joachim Harvey, Jimmie H. Spigel, David R. Dediu, Mircea Reck, Martin Cebotaru, Cristina L. Humphreys, Robin C. Gribbin, Matthew J. Fox, Norma Lynn Camidge, D. Ross